DS 3939
Alternative Names: DS 3939a; DS-3939; GT-00A ADCLatest Information Update: 22 Jun 2024
At a glance
- Originator Daiichi Sankyo Company
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 18 Aug 2023 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (IV) (NCT05875168)
- 18 Aug 2023 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Inoperable/Unresectable) in Japan (IV) (NCT05875168)